首页> 美国卫生研究院文献>The Journal of Clinical Investigation >A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus.
【2h】

A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus.

机译:来自系统性红斑狼疮患者的大多数血清都能识别SmD1 C端的新型抗原决定簇。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The SmD1 protein is a specific target for the autoantibody response in SLE. To further analyze this reactivity epitope, mapping was performed with cellulose-bound 13-mer peptides overlapping 10 amino acids (aa). In this initial approach, 4 out of 15 SLE sera recognized more than five overlapping peptides of the SmD1 C-terminus. Therefore, longer oligopeptides of up to 37 aa of this region were generated and probed for as antigens by ELISA. For the SmD1 aa 83-119 polypeptide, there was a striking increase of reactivity with 70.0% positive reactions out of 167 SLE sera. In contrast, 105 healthy control sera were negative, and only 8.3% of sera from patients with other inflammatory diseases (n = 267) exhibited a response, which was of low level only. The anti-SmD183-119 reactivity was significantly higher in anti-dsDNA antibody positive vs. negative sera (P < 0.001) and correlated with disease activity. Four of five human monoclonal anti-dsDNA antibodies also reacted with SmD183-119. The specificity for SmD1 was demonstrated by inhibition experiments and immunization of rabbits with SmD183-119 inducing SmD1-specific antibodies. In conclusion, the SmD183-119 peptide was demonstrated to be an important and highly specific target of the autoimmune response in SLE. The high sensitivity of this ELISA probably depends on a conformational epitope, which appears not to be accessible in the full-size SmD1 protein.
机译:SmD1蛋白是SLE中自身抗体应答的特异性靶标。为了进一步分析该反应性表位,使用与纤维素结合的10个氨基酸(aa)重叠的13-mer肽进行定位。在这种初始方法中,15个SLE血清中有4个识别出SmD1 C端的五个以上重叠肽。因此,产生了该区域中多达37个氨基酸的更长的寡肽,并通过ELISA探测其作为抗原。对于SmD1 aa 83-119多肽,在167个SLE血清中,具有70.0%阳性反应的反应性显着增加。相反,有105例健康对照血清为阴性,只有8.3%的其他炎症性疾病患者(n = 267)出现了反应,仅是低水平的反应。抗dsDNA抗体阳性血清的抗SmD183-119反应性显着高于阴性血清(P <0.001),并且与疾病活性相关。五个人类单克隆抗dsDNA抗体中有四个也与SmD183-119反应。通过抑制实验和用诱导SmD1特异性抗体的SmD183-119免疫兔来证明对SmD1的特异性。总之,SmD183-119肽被证明是SLE中自身免疫应答的重要且高度特异性的靶标。此ELISA的高灵敏度可能取决于构象表位,在全尺寸SmD1蛋白中似乎无法接近。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号